INTRODUCTION
Malignant melanoma is the most lethal form of skin cancer and is sixth most commonly diagnosed cancer with an increasing incidence in the United States. It is predicted that 59,940 new cases will be diagnosed and 8,110 fatalities will occur in the year 2007 (1) . At the present time, more than 1.3% of Americans will develop malignant melanoma during their lifetime (2) . Among young adults, melanoma is the most commonly diagnosed malignancy (3) . Early diagnosis and prompt surgical removal of primary melanoma lesions are patients' best hope for cures. Melanoma metastases are very aggressive and the survival time for patients with metastatic melanoma averages 3-15 months (4). Unfortunately, there is no satisfactory treatment for metastatic melanoma due to its resistance to current chemotherapy and immunotherapy regimens (5) . Early diagnosis with accurate staging of malignant melanoma is critical for appropriate treatment decisions and may provide the melanoma patients the best opportunities for cures or prolonged survival (6) (7) (8) .
The basis for current clinical diagnosis of melanoma is built on the morphologies of the melanoma tumor, which includes asymmetry, border irregularity, color variegation and diameter bigger than 6 mm. However, the diagnostic accuracy of melanoma is only about 65% (9) . Conventional non-invasive imaging techniques, such as chest radiography, ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI), are commonly used for identifying patients with melanoma metastases in lung and brain area (10) (11) (12) (13) . However, the conventional non-invasive imaging techniques have limited sensitivity (57%-81%) and specificity (45-87%) for the detection of single melanoma lesions due to lack of soft tissue contrast and/or melanoma specificity (14) (15) (16) (17) (18) (19) 18 F]FDG since they used substrates other than glucose as energy sources (22) .
Currently, melanocortin-1 (MC1) receptor is a very promising melanoma-specific target for the development of effective imaging probes. MC1 receptor is over-expressed in both melanotic and amelanotic melanomas (23) (24) (25) . The melanocortin receptors belong to the superfamily of G-protein coupled receptors (GPCRs). At the present time, five melanocortin receptors, namely MC1 to MC5 receptors, have been identified and cloned (26) (27) (28) (29) (30) (31) (32) . The MC1 receptor is expressed in melanocytes and leukocytes and is mainly involved in skin pigmentation and animal coat coloration (26, 33) . It has been demonstrated that the MC1 receptors are over-expressed on the surfaces of human and mouse melanoma cells (34) (35) (36) . More than 80% of human metastatic melanoma tumor samples have been found to display MC1 receptors (23) . Radiolabeled alpha-melanocyte stimulating hormone (α-MSH) peptide analogues exhibit nanomolar MC1 receptor binding affinities, making them very promising melanoma-specific imaging probes for melanoma detection. This review highlights the recent developments of radiolabeled MC1 receptor-targeting α-MSH peptides as imaging probes for melanoma imaging. Two types of radiolabeled α-MSH peptides, namely linear and metal-cyclized peptides, will be the focus of this review. The results highlighted in this review demonstrate the rationales for developing new MC1 receptor-targeting α-MSH peptide radiopharmaceuticals as melanoma-specific imaging probes for melanoma detection.
3.
RADIOLABELED Figure 1 ), which is involved in the control of skin pigmentation. The biological activity of α-MSH is mediated through interactions with the MC1 receptor (37) . MC1 receptor agonists are internalized into the melanoma cells upon binding to MC1 receptors (38, 39) . During the 1970s to 1980s, intensive research efforts were focused on the development of tritium-labeled linear α-MSH analogues (40) (41) (42) (43) (44) (Figure 1 ), which is referred to as a "gold" standard due to its sub-nanomolar receptor binding affinity (39) . However, the utilization of 125 I-NDP-MSH is mainly limited in in vitro studies due to the dehalogenation reaction of 125 I-NDP-MSH in vivo (44) . Hence, several halogen labeling approaches were developed to reduce the in vivo dehalogenation. It was reported that NDP-MSH radiolabeled with N-succinimidyl 3-iodobenzoate (SIB) or N-succinimidyl 4-iodobenzoate (PIB) was inert to the in vivo dehalogenation (50, 51 F-PFB-NDP-MSH have been reported in melanoma-bearing mice.
Another method to radiolabel linear α-MSH peptide analogues is through the conjugation of a bifunctional radionuclide chelator. Bifunctional chelators such as Ac-Cys-Gly-Cys-Gly-(CGCG), tetrafluorophenyl mercato-acetylglycylglycyl-gamma-aminobutyrate (MAG 2 ), diethylenetriamene pentaacetate (DTPA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) are usually attached to the N-terminus of the α-MSH peptides. CGCG and MAG 2 are N 2 S 2 and N 3 S chelation systems that are able to easily coordinate 99m Tc or 188 Re (53, 54) . It was reported that 99m Tc-CGCG-NDP-MSH ( Figure 1 ) exhibited greater tumor to blood and tumor to muscle ratios than 99m Tc-MAG 2 -NDP-MSH and 125 ITyr 2 -NDP-MSH at 30 min, 1 and 4 h post-injection (54). However, the moderate melanoma uptake of 99m Tc-CGCG-NDP-MSH (6.52±1.11 %ID/g at 30 min post-injection) prevented its further evaluation. DTPA and DOTA are good metal chelators and are able to form stable complexes with a variety of radiometals. Indium-111-labeled DTPAbis-NDP was reported to be able to image melanoma with 89% sensitivity in a limited phase I clinical trial (55) . However, high renal and liver uptake compromised its imaging capabilities in those organs. Recently, 111 In-labeled short linear DOTA-conjugated NDP analogues, such as 111 In-DOTA-NDP-MSH and 111 In-DOTA-MSH OCT ( Figure  1 ), were reported as potential melanoma imaging agents (24, 56) . 111 In-DOTA-MSH OCT exhibited 4.31±0.30 %ID/g and 1.17±0.13 %ID/g at 4 and 24 h post-injection in B16/F1 melanoma-bearing mice. Although 111 In-DOTA-MSH OCT exhibited significant (p<0.05) lower tumor uptake than 111 In-DOTA-NDP-MSH at 4, 24 and 48 h postinjection, the accumulation of 111 In-DOTA-MSH OCT activity in normal organs was lower than that of 111 In-DOTA-NDP-MSH at 4, 24 and 48 h post-injection except for the kidneys (24) . The autoradiographs of tissue section with metastatic melanoma showed that 111 In-DOTA-MSH OCT was taken up by both melanotic and amelanotic melanoma metastases (24) . More recently, 111 In-DOTANAPamide ( Figure 1 ) was reported to exhibit a more favorable biodistribution profile (higher tumor uptake and less renal uptake) than 111 In-DOTA-MSH OCT in the same melanoma mouse model (57) . 111 In-DOTA-NAPamide displayed the tumor uptake of 7.56±0.51 %ID/g and the kidney uptake of 5.06±0.32 %ID/g at 4 h post-injection. Compared to the 111 In-DOTA-MSH OCT , DOTA was coupled to the side chain of Lys on the C-terminus rather than N-terminus in 111 In-DOTA-NAPamide. The amino group at the N-terminus was acetylated and the Gly 10 was introduced in the peptide of 111 In-DOTA-NAPamide. All these changes resulted in the improvement of the tumor to kidney uptake ratio of the 111 In-DOTA-NAPamide compared to the 111 In-DOTA-MSH OCT . The substitution of 111 In with 67 Ga further improved the tumor to kidney ratio of 67 Ga-DOTA-NAPamide (57). The autoradiographs of tissue section with metastatic melanoma showed that 67 Ga-DOTA-NAPamide was taken up by both melanotic and amelanotic melanoma metastases, highlighting the suitability of 67 Ga-DOTA-NAPamide for melanoma metastases imaging. Melanoma lesions were visualized with 68 Ga-DOTA-NAPamide in preclinical PET studies (57) , demonstrating the potential of 68 Ga-DOTANAPamide as a PET imaging probe for melanoma detection.
RADIOLABELED METAL-CYCLIZED ALPHA-MSH PEPTIDE ANALOGUES FOR MELANOMA IMAGING
Radiolabeled metal-cyclized α-MSH peptide analogues are another class of peptides with higher melanoma tumor uptake and superior tumor retention. Peptide cyclization was used to improve the in vivo stability and binding affinity of the peptide (58) (59) (60) . Cyclic peptides possess less conformational freedom than linear peptides due to the stabilization of secondary structures such as beta turns, making cyclic peptides better fit receptor binding pocket which enhances binding affinities. A novel class of metal-cyclized α-MSH peptide analogues was developed for melanoma imaging and therapy over the past several years (39, 56, (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) (71) . The cyclic α-MSH peptide analogues incorporated non-radioactive or radioactive metals into their structures while retaining high affinities for MC1 receptors. Cyclization and radiolabeling of the peptide could be simultaneously achieved during the radiolabeling process. The metal cyclization made the peptide resistant to chemical and proteolytic degradation in vivo (39, 61) . Initially, the α-MSH peptide analogue (Cys 4,10 , D-Phe 7 )-α-MSH 4-13 (APOMSH) was synthesized and cyclized with non-radioactive rhenium (61) . However, the rhenium cyclization dramatically decreased the binding affinity of ReO-APOMSH (K i =66 nM). Hence, another Cys was introduced to the N-terminus of the peptide sequence to yield (Cys (61) . The favorable biodistribution of 99m Tc-CCMSH opened the avenue for using this class of metal-cyclized peptide radiopharmaceuticals for melanoma imaging and therapy.
Although
99m Tc-CCMSH exhibited high receptormediated melanoma uptake in B16/F1 melanoma-bearing mice, relatively high kidney uptake (14.60±1.88 %ID/g at 4 h post-injection) was observed. It was critical to address this challenge to promote the clinical evaluation of this class of imaging probes for melanoma detection. It was postulated that non-specific renal activity accumulation was due to the electrostatic interaction between positively charged peptides and negatively charged surface of tubule cells, as the peptides were filtered in the glomerulus and reabsorbed in the cells of the proximal tubule (72) . The strategies of infusing basic amino acids (lysine or arginine) and structural modification of the peptide (increasing the overall negative charge) were employed to decrease the renal uptake of radiolabeled peptides (62, 73, 74) . The initial effort to reduce the non-specific kidney retention of the 99m Tc-CCMSH focused on co-injection of L-lysine with the 99m Tc-CCMSH and the substitution of Lys 11 with Gly or Nle (39) . The co-injection of L-lysine decreased the renal uptake of 99m Tc-CCMSH by 50%. Compared to the coinjection of L-lysine, the substitution of Lys 11 with Gly or Nle in 99m Tc-CCMSH analogues exhibited more profound effects in reducing the renal uptakes of the peptides. However, the substitution of Lys 11 with Gly or Nle sacrificed the high tumor uptake values of the peptides (39) , demonstrating that the Lys 11 residue in 99m Tc-CCMSH was critical to the melanoma targeting in vivo.
The success of the co-injection of L-lysine in renal uptake reduction demonstrated that the overall positive charge of the peptide plays an important role on the renal uptake of 99m Tc-CCMSH. Hence, more research on structural modification of Lys 11 was investigated to optimizing the peptide sequence of CCMSH (75) . Five new CCMSH peptide analogues were synthesized by substituting Lys 11 with Arg, Orn, Met, Gln or Glu to examine the effects of positive charge distribution, structure of the side chain, neutral charge and negative charge at the 11 th position on the tumor and renal uptakes of CCMSH peptide analogues (75) . The introduction of a negative charged or neutral charged amino acid at the 11 th position dramatically reduced the renal uptakes as well as tumor uptakes of the peptides. The positive charge at 11 th position was responsible for the high tumor and renal uptakes of the peptides in vivo. Surprisingly, the substitution of Lys 11 with Arg 11 resulted in 30% higher tumor uptake and 43% less renal uptake of 188 Re-(Arg 11 )CCMSH than that of 188 Re-CCMSH (75) . The increased tumor uptake and decreased renal uptake were likely attributed to the involvement of the amino acid at the 11 th position in the receptor binding as well as the overall charge distribution of the peptide. Arg crucial amino acid which perfectly balanced the structure of the peptide.
Although [
18 F]FDG PET is the most commonly used radiopharmaceutical for the diagnosis and staging of melanoma, the detection of small melanoma metastases (<10 mm) remains challenging.
99m Tc-(Arg 11 )CCMSH (Figure 2 ) was prepared to examine its melanoma targeting properties and pharmacokinetics in B16/F1 primary and B16/F10 metastatic melanoma-bearing mice (69) .
99m Tc-(Arg 11 )CCMSH exhibited high receptor-mediated tumor uptake (14.03±2.58 %ID/g at 1 h post-injection) and fast whole-body clearance (83.82±3.50 %ID at 4 h postinjection) in B16/F1 primary melanoma-bearing mice. The 99m Tc-(Arg 11 )CCMSH activity in metastatic melanomabearing lung was 5.32 times the activity in normal lung. Both primary and metastatic melanoma lesions were clearly visualized with 99m Tc-(Arg 11 )CCMSH by Micro-SPECT/CT images, highlighting the potential of 99m Tc-(Arg 11 )CCMSH as an effective imaging probe for primary and metastatic melanoma detection (Figure 3 ). Radiohalogenated α-MSH peptide analogues were re-investigated since metal cyclization had been The metal chelator DOTA was coupled to the Re(Arg 11 )CCMSH to enable selective delivery of a wide variety of radionuclides for imaging and therapy (56, 63, 69) , since DOTA can form stable complexes with a wide variety of diagnostic and therapeutic radionuclides. Nonradioactive rhenium was employed to cyclize the peptide. 111 In-DOTA-Re(Arg 11 )CCMSH (Figure 2) Cu as PET imaging probes and evaluated for melanoma detection, since micro-PET allows high-resolution image and quantification of the radioactivity (64) (Figure 4) . 86 Y-labeled and 64 Cu-labeled DOTA-Re(Arg 11 )CCMSH exhibited slightly lower melanoma uptakes than 111 In-DOTA-Re(Arg 11 )CCMSH due to possible differences in the vascularization of the melanoma tumors and the lower specific activity of 64 Cu. However, the release of 64 Cu from the 64 Cu-DOTARe(Arg 11 )CCMSH in vivo resulted in high liver uptake which might compromise its applications in the melanoma metastases detection in the liver (64) . Hence, a cross-bridged cyclam chelator (CBTE2A) (Figure 2 ) was employed to substitute the DOTA to increase the stability of 64 Cu coordination. The substitution of DOTA with CBTE2A dramatically reduced the 64 Cu uptake in normal organs and greatly improved tumor to normal organ uptake ratios (70) , demonstrating that CBTE2A chelator could form stable complex with 64 Cu and solve the loss of 64 Cu from DOTA in vivo. Small animal PET images of ) CCMSH. The PET images also showed that the administering of a blockade dose substantially reduced tumor uptake of both agents demonstrating that tumor uptake was receptor-mediated. It was also evident from the 86 Y-images that background accumulation was very low (i.e., low non-target tissue uptake) and that in the non-blockade mouse very little tracer accumulation was noted .Reproduced by permission from the Society of Nuclear Medicine (64).
CONCLUSIONS
Peptide-based radiopharmaceuticals, targeting receptors over-expressed on the surface of tumor cells, continue to receive great interest toward the development of cancerspecific diagnostic and therapeutic agents. The radiolabeled α-MSH peptide analogues highlighted in this review are two types of representative examples targeting MC1 receptors over-expressed on melanoma cells. The results described in this review demonstrated the strategies used to develop radiolabeled α-MSH peptide analogues for melanoma targeting. Radiolabeled metal-cyclized α-MSH Since tumors did not grow in exactly the same location from animal to animal, the slices might show different tissues in addition to the tumors. The PET images showed that the administration of a blockade dose substantially reduced tumor uptake of the agent by such an extent that the tumor was difficult to delineate. It was also evident that the background accumulation was very low resulting in excellent tumor contrast. (T = tumor, K = kidney). (B) MicroPET/CT co-registered images of B16F1 tumor bearing mice 2 h after tail vein injection of 5.5 MBq (500 ng) of 64 Cu-CBTE2A-Re(Arg 11 )CCMSH. The images shown were 1 mm slices and the slices shown were through the center of the tumor volume. Reproduced by permission from the Society of Nuclear Medicine (70) . peptide analogues exhibit great potential as melanomaspecific imaging probes for the clinic. Although the radionuclides involved in this review primarily focused on diagnostic radionuclides, it is important to note that these peptide analogues can be radiolabeled with therapeutic radionuclides for targeted radionuclide therapy. The results from radiolabeled α-MSH peptide analogues and radiolabeled peptides for other receptors such as somatostatin, integrin, guanylin/guanylate cyclase-C and bombsin provide very strong evidence for the suitability and feasibility of their utilization in the early diagnosis and effective treatment of cancer. Early diagnosis and effective treatment will provide the caner patients the best opportunities for cures or prolonged survival. Clearly, there is a great need of more effort and resources to develop peptide radiopharmaceuticals for cancer imaging and therapy. 
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